Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study

These real-world data on first-line biologics show no differences in 12-month effectiveness outcomes for vedolizumab- vs. infliximab-treated biologic-naive patients with CD. Vedolizumab may have a more favorable safety profile vs. infliximab in patients with complicated and noncomplicated disease.